[go: up one dir, main page]

WO2023068855A1 - Composition pour le soulagement, la prévention ou le traitement du cancer à l'aide d'une souche de veillonella parvula ayant une activité anticancéreuse - Google Patents

Composition pour le soulagement, la prévention ou le traitement du cancer à l'aide d'une souche de veillonella parvula ayant une activité anticancéreuse Download PDF

Info

Publication number
WO2023068855A1
WO2023068855A1 PCT/KR2022/016090 KR2022016090W WO2023068855A1 WO 2023068855 A1 WO2023068855 A1 WO 2023068855A1 KR 2022016090 W KR2022016090 W KR 2022016090W WO 2023068855 A1 WO2023068855 A1 WO 2023068855A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
strain
kbl1041
present
parbula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2022/016090
Other languages
English (en)
Korean (ko)
Inventor
고광표
윤성현
유현주
최성훈
조선아
김현정
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Kobiolabs Inc
Original Assignee
Seoul National University R&DB Foundation
Kobiolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University R&DB Foundation, Kobiolabs Inc filed Critical Seoul National University R&DB Foundation
Publication of WO2023068855A1 publication Critical patent/WO2023068855A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium

Definitions

  • the present invention relates to the use of Veillonella parvula strains for preventing, treating or improving cancer having anticancer effects.
  • Probiotics refer to microorganisms and products produced by the microorganisms having antibacterial activity and enzymatic activity that help the intestinal microbial balance.
  • probiotics are defined as live bacteria in the form of single or complex strains that are supplied to humans or animals in the form of dry cells or fermentation products to improve the intestinal flora.
  • Probiotics have the characteristics of non-pathogenicity and non-toxicity, inhabit the human intestine, and must survive while going to the intestine, so they must have resistance to acids, enzymes, and bile in the intestinal environment.
  • probiotics must retain viability and activity prior to consumption in delivery foods, must be sensitive to antibiotics used to prevent infection, and must not contain antibiotic-resistant plasmids.
  • Probiotics refer to microorganisms and products produced by the microorganisms having antibacterial activity and enzymatic activity that help the intestinal microbial balance.
  • probiotics are defined as live bacteria in the form of single or complex strains that are supplied to humans or animals in the form of dry cells or fermentation products to improve the intestinal flora.
  • Probiotics have the characteristics of non-pathogenicity and non-toxicity, inhabit the human intestine, and must survive while going to the intestine, so they must have resistance to acids, enzymes, and bile in the intestinal environment.
  • probiotics must retain viability and activity prior to consumption in delivery foods, must be sensitive to antibiotics used to prevent infection, and must not contain antibiotic-resistant plasmids.
  • probiotics include Bacillus sp. , which has an excellent ability to produce digestive enzymes (amylase, protease, lipase, cellulase, and phosphatase), Lactobacillus sp. Examples include photosynthetic bacteria that use substances (ammonia, hydrogen sulfide, amines, etc.) in metabolic processes to prevent odors.
  • Veillonella parvula which is treated in the present invention, is a microorganism found in the human intestine, and is one of probiotics that have a beneficial effect on the intestinal environment while living in the human intestine.
  • cancer refers to a group of abnormal cells generated by continuous division and proliferation when the balance between cell division and death is destroyed for various reasons, and is also referred to as a tumor or a neoplasm. In general, it develops in more than 100 different body parts, including organs, white blood cells, bones, and lymph nodes, and develops into serious symptoms through infiltration into surrounding tissues and metastasis to other organs (WHO, 2006).
  • causes of cancer include environmental or external factors such as chemicals, viruses, bacteria, and ionizing radiation, and internal factors such as congenital genetic mutations (Klauunig & Kamendulis, Annu Rev Pharmacol Toxicol 2004, 44:239-267 ).
  • the inventors of the present invention have devoted themselves to probiotics research as a method that can replace drug-based treatment of cancer for which there is no conventional satisfactory treatment, and as a result, the cancer growth inhibitory effect of Veillonella parvula strains A new discovery of excellence led to the completion of the present invention.
  • An object of the present invention is to provide a probiotic strain showing excellent effects in the alleviation, prevention or treatment of cancer, a composition containing the same, and a composition for co-administration thereof with an anti-cancer therapeutic agent.
  • the present invention provides a Veillonella parvula KBL1041 strain deposited with accession number KCTC 5019.
  • the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising at least one strain selected from the group consisting of at least one strain, a culture of the strain, a lysate of the strain, and an extract of the strain. .
  • the present invention provides a food composition for preventing or improving cancer, comprising at least one selected from the group consisting of the strain, culture of the strain, lysate of the strain, and extract of the strain.
  • the present invention is Veillonella parvula ( Veillonella parvula ) strain, a culture of the strain, a lysate of the strain, and a drug for preventing or treating cancer, including at least one selected from the group consisting of an extract of the strain
  • a scientific composition is provided.
  • the present invention is a Veillonella parvula strain, a culture of the strain, a lysate of the strain, and a food composition for preventing or improving cancer, including at least one selected from the group consisting of an extract of the strain to provide.
  • the present invention provides a feed composition comprising at least one selected from the group consisting of a Veillonella parvula strain, a culture of the strain, a lysate of the strain, and an extract of the strain.
  • the Bailonella parbula strain according to the present invention specifically the KCTC 5019 strain (KBL1041 strain), and its culture, lysate and extract show the effect of reducing the size of tumors when administered to animals with cancer, Increases immune cells related to improvement or treatment of
  • the composition comprising at least one selected from the group consisting of the strain of the present invention, its culture, lysate and extract exhibits cancer alleviation, prevention or treatment effects As a result, it can be used industrially very usefully.
  • Figure 1 shows the secretion of IFN- ⁇ , IL-10 and IL-12p70, which are anticancer-related cytokines, by treating splenocytes and BMDC with the KBL1041 strain (KCTC 5019 strain) of the present invention compared with other strains through ELISA analysis is a result
  • Figure 2 is a diagram showing the results of analyzing the death rate (%) of cancer cells after co-cultivating the KBL1041 strain of the present invention with splenocytes and MC38 colorectal cancer cells.
  • Figure 3 is a graph showing the tumor volume increase inhibitory effect when the KBL1041 strain of the present invention was administered to mice induced with colorectal cancer and melanoma.
  • Figure 4 is a result of analyzing immune cells through flow cytometry after administering the KBL1041 strain of the present invention to mice induced with colon cancer.
  • Figure 5 is a graph showing changes in tumor volume and weight measured in the KBL1041 strain of the present invention in a neutrophil-free model using an anti-Ly6G antibody.
  • Figure 6 is a graph showing changes in tumor volume and weight measured after administration of KBL1041 of the present invention to NSGA mice in which only neutrophils among immune cells function normally.
  • FIG. 9 is a view showing the results of analyzing the death rate (%) of MC38 colon cancer cells co-cultured with neutrophils isolated from colon cancer-induced mice administered with the KBL1041 strain of the present invention.
  • 10 is a result of analyzing the ratio of neutrophils having anticancer efficacy by performing flow cytometry on tumor tissues obtained after administration of the KBL1041 strain of the present invention to mice induced with colon cancer.
  • MFI mean fluorescence intensity
  • ROS reactive oxygen species
  • MFI 13 is a flow cytometry analysis result of measuring the mean fluorescence intensity (MFI) of TLR2 and TLR4 after administering the KBL1041 strain of the present invention to mice induced with colon cancer.
  • MFI mean fluorescence intensity
  • FIG. 14 is a graph showing changes in tumor volume and weight measured after single or combined administration of the KBL1041 strain of the present invention and an anti-TLR2 antibody to mice induced with colon cancer.
  • 15 is a view showing the results of analyzing the death rate (%) of cancer cells after co-cultivating MC38 cells co-cultured with neutrophils treated with an anti-TLR2 antibody with KBL1041 strain.
  • 16 is a graph showing changes in tumor volume and weight measured after single or combined administration of the KBL1041 strain of the present invention and an anti-PD1 antibody, an immuno-anticancer agent, to mice induced with colon cancer.
  • Figure 17 analyzes the survival rate of cancer cells after treatment with KBL1041 strain in lung cancer cell line A549, breast cancer cell line MDA-MB-231, liver cancer cell line HepG2, melanoma cell line B16F10, pancreatic cancer cell line PANC1, renal cancer cell line RENCA, and colon cancer cell line MC38 it is a graph
  • FIG. 18 is a view showing analysis of non-settled formation ability of cancer cells after treatment of strain KBL1041 with lung cancer cell line A549.
  • FIG. 19 is a view showing analysis of non-settled formation ability of cancer cells after KBL1041 strain was treated with renal cancer cell line RENCA.
  • the present invention is a Veillonella parvula strain, a culture of the strain, a lysate of the strain, and a pharmaceutical composition for preventing or treating cancer, comprising at least one member selected from the group consisting of an extract of the strain to provide.
  • the Bailonella parbula strain may be a KCTC 5019 strain, wherein the KCTC 5019 strain is a known strain classified as a Parbula species of the genus Veilonella, and can be easily purchased by a person skilled in the art or can be obtained In the present specification, the KCTC 5019 strain is also referred to as “KBL1041 strain”.
  • the strain is excellent in the effect of preventing, treating or improving cancer, it can be used for this purpose.
  • the strain may have an activity of increasing the number and activity of immune cells in cancer cells.
  • composition of the present invention may further include other strains in addition to the above strains, and may further include other Bailonella parbula strains.
  • strains may be included in the form of live cell cells, dead cell cells and dried strains, cultures thereof, lysates thereof, or extracts thereof.
  • the term "culture” refers to a product obtained by culturing a strain in a known medium, and the product may include the strain itself.
  • the medium may be selected from known liquid medium or solid medium, and may be, for example, MRS liquid medium, GAM liquid medium, MRS agar medium, GAM agar medium, and BL agar medium, but is not limited thereto.
  • lysate refers to any product obtained by disrupting a strain by enzyme treatment, homogenization, or ultrasonic treatment.
  • extract refers to a product obtained by extracting a strain with a known extraction solvent.
  • extract includes a water extract and/or an organic solvent extract of the strains according to the present invention.
  • the organic solvent extract of the strain according to the present invention may be an organic solvent extract having 1 or more and 10 or less carbon atoms.
  • a substituted or unsubstituted alcohol extract having 1 to 10 carbon atoms, 1 to 5 carbon atoms, or 1 to 3 carbon atoms may be used as the extraction solvent.
  • alcohol extracts such as, for example, methanol extracts, ethanol extracts, iso-propanol extracts, n-propanol extracts, n-butanol extracts, iso-butanol extracts, tert-butanol extracts and/or phenol extracts; ether extracts such as dialkyl ethers such as dimethyl ether, diethyl ether, and methyl ethyl ether; n-hexane, ethyl acetate, dichloromethane, chloroform and/or acetone extracts.
  • ether extracts such as dialkyl ethers such as dimethyl ether, diethyl ether, and methyl ethyl ether
  • n-hexane ethyl acetate, dichloromethane, chloroform and/or acetone extracts.
  • live cell refers to the strain itself of the present invention
  • dead cell refers to a strain that has been sterilized by heating, pressurization, or drug treatment.
  • composition of the present invention may be provided as a composition capable of being further combined with pharmaceutically acceptable additives such as carriers or media.
  • the additives used in the present invention are solvents, dispersants, coatings, absorption accelerators, controlled release agents (i.e. sustained release agents), and one or more inactive excipients (starch, polyols, granules, microfine cellulose, microcrystalline cellulose). (including, for example, cellphere, cellphere beads, diluents, lubricants, binders, disintegrants, etc.), etc.
  • tablet formulations of the disclosed compositions may be standard aqueous or Non-limiting examples of excipients for use as pharmaceutically acceptable carriers and pharmaceutically acceptable inert carriers and the additional ingredients include binders, fillers, disintegrants, lubricants. , antimicrobial agents and coating agents.
  • the content of the additives included in the pharmaceutical composition is not particularly limited and may be appropriately adjusted within the range of content used in conventional formulations.
  • cancer medically refers to a problem in the normal division, differentiation, or death control function of cells, resulting in abnormal overproliferation, infiltration of surrounding tissues or organs, formation of lumps, and destruction or transformation of existing structures. means any condition. Due to such uncontrolled and abnormal cell growth, a cell mass called a tumor is formed, infiltrating surrounding normal tissues or organs, destroying the normal tissues or organs, and taking the life of the subject.
  • prevention means delaying the onset of a disease, disorder or condition.
  • treatment means, unless otherwise stated, to reverse, alleviate, inhibit the progress of, or reverse the disease or condition to which the term applies, or one or more symptoms of the disease or condition, or It means to prevent, and the term “treatment” used in the present invention refers to the act of treating when "treating" is defined as above.
  • treatment or therapy for a disease in a mammal may include one or more of the following:
  • composition of the present invention according to the conventional method according to each purpose of use, oral formulations such as solutions, suspensions, powders, granules, tablets, capsules, pills, extracts, emulsions, syrups, aerosols, injections of sterile injection solutions It can be formulated and used in various forms such as oral administration or parenteral administration through various routes including intravenous, intraperitoneal, subcutaneous, intradermal, intramuscular, spinal, intrathecal, or rectal topical administration or injection.
  • the dosage may vary depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, administration period or interval, excretion rate, constitutional specificity, nature of the preparation, severity of the disease, etc. there is.
  • liquid formulation refers to a medicine to be taken in the form of a liquid medicine dissolved in water or an organic solvent. Compared to suspensions or solid formulations, liquid formulations have the advantage of more effective drug absorption from the intestinal tract to the systemic circulation, and the liquid formulations may contain additional solutes in addition to pharmaceuticals, and additives providing color, odor, sweetness, or stability. may also be included.
  • the term “suspending agent” refers to any agent capable of providing the desired solubility and/or dispersibility of an alginate-containing composition, i.e., an aqueous formulation that is substantially clear and free of sedimentation and lumps.
  • powder refers to finely divided drugs, chemicals, or a dry mixture of both. “Powder” may include a mixture in a lyophilized state.
  • powders may contain conventional additives used in lyophilized formulations such as lyophilized strains and lyophilized preservatives.
  • the term "granule” refers to a drug or a mixture of drugs in the form of granules, which usually passes through a sieve of 4.76 to 20 mm.
  • Granules are generally produced by wetting the powder or mixture of powders and passing the mass through a sieve or granulator of appropriate mesh size depending on the size of the granules required. Since granules, like powders, are granular, the degree of contact of the drug to the tongue is high, so when a drug having a bitter taste is used in the form of granules, it may cause discomfort to patients, especially children or the elderly.
  • tablette means a powdered medicine made easy to take by compressing it into a small disc shape. Tablets may include uncoated tablets, film-coated tablets, coated tablets, multilayer tablets, press-coated tablets, inner core tablets, orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, and dissolving tablets.
  • a pharmaceutical composition refers to a product made by filling a drug into a capsule in the form of a liquid, suspension, water, powder, granule, mini-tablet, or pellet, or encapsulated with a capsule base.
  • a pharmaceutical composition according to one embodiment may include a lyophilized strain.
  • the pharmaceutical composition of one embodiment may be formulated in the form of a capsule formulation of the lyophilized strain.
  • the storage period of the strain can be improved by minimizing the loss of the strain that may occur due to heat.
  • the biological activity of the strain can be inactivated to improve formulation stability, and the strain can be more easily induced to rehydrate than other formulation methods, so that the original activity and growth ability can be quickly restored after supplying water to the dry strain.
  • the freeze-dried preparation is easy to formulate, such as tableting and encapsulation, and can be prepared in various dosage forms.
  • regeneration which is the most important feature of LBP (Live Biotherapeutic Products) such as strain preparations, can proceed very stably in freeze-dried strains.
  • the strain when the strain is formulated by lyophilization, skim milk, sugars (eg, trehalose, sucrose, maltose or glucose, etc.), sugar alcohols (eg, to prevent a rapid decrease in activity during freeze-drying of the strain)
  • sugars eg, trehalose, sucrose, maltose or glucose, etc.
  • sugar alcohols eg, to prevent a rapid decrease in activity during freeze-drying of the strain
  • mannitol, inositol, or sorbitol, etc. may be mixed with conventional freeze-drying preservatives (or protecting agents) used in the art and then freeze-dried.
  • any lyophilization method commonly used in the art can be used without particular limitation.
  • pill is meant to encompass small, round solid dosage forms containing multiparticulates mixed with binders and other excipients.
  • the term "syrup" means a thick homemade sugar or sugar substitute.
  • the syrup is an easy-to-take medicine with an unpleasant taste, such as a bitter taste, in a liquid form, and is particularly suitable for use by children.
  • the syrup may include, in addition to purified water and extract, sugar or a substitute for sugar used to give sweetness and viscosity, an antibacterial preservative, a flavoring agent, or a coloring agent, but is not limited thereto.
  • sweeteners examples include, but are not limited to, white sugar, mannitol, sorbitol, xylitol, aspartame, stevioside, fructose, lactose, sucralose, saccharin, or menthol.
  • injection refers to an aseptic preparation applied to the body through the skin or mucous membrane, and in particular, any form of administration such as subcutaneous injection, intramuscular injection, intradermal injection, and intraperitoneal injection may be used as an injection route. It is possible, and the dosage form is selected according to the characteristics of each pharmacologically active substance.
  • the composition of the present invention may be a composition for oral administration.
  • oral administration means that the active substance is administered to the gastrointestinal tract through the oral route for absorption.
  • Non-limiting examples of the formulation for oral administration include tablets, troches, lozenges, aqueous suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs, and the like.
  • a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin; excipients such as dicalcium phosphate and the like; disintegrants such as corn starch or sweet potato starch; Lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate, or polyethylene glycol may be used, and sweeteners, aromatics, syrups, and the like may also be used.
  • a liquid carrier such as fatty oil may be additionally used in addition to the above-mentioned materials.
  • the pharmaceutical composition of the present invention may be provided as an enteric-coated enteric preparation, particularly as a unit dosage form for oral use.
  • Enteric coating in the present specification includes all types of pharmaceutically acceptable known coatings that are not decomposed by gastric acid and the coating is maintained, but sufficiently decomposed in the small intestine so that the active ingredient can be released into the small intestine. do.
  • the "enteric coating” of the present invention is maintained for at least 2 hours when artificial gastric juice such as an HCl solution of pH 1 is brought into contact at 36°C to 38°C, preferably after that, a KH 2 PO 4 buffer solution of pH 6.8. Refers to coatings that disintegrate within 30 minutes in artificial intestinal juices such as
  • the enteric coating of the present invention is coated in an amount of about 16 to 30, preferably 16 to 20 or 25 mg or less per core.
  • the thickness of the enteric coating of the present invention is 5 to 100 ⁇ m, preferably 20 to 80 ⁇ m, satisfactory results are obtained as an enteric coating.
  • the material of the enteric coating is appropriately selected from known high molecular materials. Suitable polymeric materials are described in a number of well-known literature (L. Lachman et al., The Theory and Practice of Industrial Pharmacy, 3rd edition, 1986, pp. 365-373 H. Sucker et al., Pharmazeutician Technologie, Thieme, 1991, pp. 355-359; Hagers Handbuchder pharmazeutician fürtechnik, 4th edition, Vol. 7, pp.
  • the enteric coating of the present invention can be prepared using a conventional enteric coating method in which an enteric coating solution is sprayed onto a core.
  • Suitable solvents used in the enteric coating process include alcohols such as ethanol, ketones such as acetone, and halogenated hydrocarbon solvents such as dichloromethane (CH 2 Cl 2 ), and a mixed solvent of these solvents may be used.
  • An emollient such as di(di)-n-butylphthalate or triacetin is added to the coating solution in a ratio of 1 to about 0.05 to about 0.3 (coating material to softener). It is appropriate to carry out the spraying process continuously and it is possible to adjust the amount of spraying taking into account the conditions of the coating.
  • the spray pressure can be varied, and satisfactory results are generally obtained with spray pressures of about 1 to about 1.5 bar.
  • the composition of the present invention may be a composition for parenteral administration.
  • parenteral administration means intravenous, intraperitoneal, subcutaneous, intradermal, intramuscular, spinal, intrathecal or rectal topical administration or injection.
  • Parenteral administration is by injecting a suppository preparation, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection.
  • the composition may be mixed in water with a stabilizer or a buffer to prepare a solution or suspension, which may be prepared in a unit dosage form in an ampoule or vial.
  • the preferred dosage of the composition of the present invention depends on the condition and weight of the patient, age, sex, health condition, dietary constitution specificity, the nature of the preparation, the severity of the disease, the administration time of the composition, the administration method, the administration period or interval, the excretion rate, And the range may vary depending on the type of drug, and may be appropriately selected by a person skilled in the art. For example, it may be in the range of about 0.1 to 10,000 mg/kg, but is not limited thereto, and may be divided and administered once or several times a day.
  • the present invention provides a food composition for preventing or alleviating cancer or a food additive composition comprising at least one selected from the group consisting of a Bailonella parbula strain, a culture of the strain, a lysate of the strain, and an extract of the strain to provide.
  • the Bailonella parbula strain may be a KCTC 5019 strain.
  • the food may be a health functional food.
  • the food composition or composition for food additives may be included in foods effective in preventing or alleviating cancer.
  • the food composition of the present invention can be easily utilized as a main ingredient, supplementary ingredient, food additive, health functional food or functional beverage of food.
  • the food composition means a natural product or processed product containing one or more nutrients, and preferably means a product that can be directly eaten through a certain degree of processing, and in a conventional sense, food, It refers to food additives, health functional foods, and functional beverages.
  • Foods to which the food or food additive composition according to the present invention can be added include, for example, various foods, beverages, chewing gum, tea, vitamin complexes, and functional foods.
  • food includes special nutritional food (eg, formula milk, infant food, baby food, etc.), processed meat product, fish meat product, tofu, jelly, noodles (eg, ramen, noodles, etc.), bread, health supplement food, seasoning Foods (eg, soy sauce, soybean paste, gochujang, mixed paste, etc.), sauces, confectionery (eg, snacks), candies, chocolates, chewing gum, ice cream, dairy products (eg, fermented milk, cheese, etc.), other processed foods, kimchi, It includes, but is not limited to, pickled foods (various types of kimchi, pickled vegetables, etc.), beverages (eg, fruit drinks, vegetable drinks, soy milk, fermented beverages, etc.), and natural seasonings (eg, ramen soup, etc.).
  • the food, beverage or food includes, but
  • the term “health functional food” refers to a food group or food composition that has added value so that the function of the food acts for a specific purpose by using physical, biochemical, or bioengineering methods, etc. It refers to food designed and processed to fully express the body's regulatory functions related to disease prevention and recovery.
  • the functional food may include food additives that are acceptable in food science, and may further include appropriate carriers, excipients, and diluents commonly used in the manufacture of functional foods.
  • the food containing the food composition of the present invention is various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers (cheese, chocolate, etc.), pectins acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. and can be used.
  • the amount of the composition according to the present invention may be 0.001% to 100% by weight of the total weight of the food, preferably 1% to 99% by weight. %, and in the case of beverages, it may be included in a ratio of 0.001 g to 10 g, preferably 0.01 g to 1 g based on 100 mL, but for health and hygiene purposes or health control purposes In the case of long-term ingestion, it may be less than the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
  • the food or food additive composition of the present invention may be prepared by adding a Veilonella parbula strain, such as a Veilonella parbula KCTC 5019 strain, independently or to an acceptable carrier, or in the form of a composition suitable for consumption by humans or animals.
  • a Veilonella parbula strain such as a Veilonella parbula KCTC 5019 strain
  • an acceptable carrier or in the form of a composition suitable for consumption by humans or animals.
  • it can be added to and used in foods that do not contain other probiotic bacteria and foods that already contain some probiotic bacteria.
  • the present invention provides an animal feed or composition for addition to animal feed comprising at least one selected from the group consisting of a Bailonella parbula strain, a culture of the strain, a lysate of the strain, and an extract of the strain.
  • the Bailonella parbula strain may be a KCTC 5019 strain.
  • the additive for animal feed of the present invention may be in the form of a dry or liquid preparation, and may further contain other non-pathogenic microorganisms in addition to the Bailonella parbula strain, for example, the Bailonella parbula KCTC 5019 strain.
  • the feed raw materials include various grains and soybean proteins, peanuts, peas, sugar beets, pulp, and grain by-products , animal intestine powder, fish meal powder, etc. may be used, and these may be used unprocessed or processed without limitation.
  • the present invention provides a therapeutically effective amount of a pharmaceutical composition comprising at least one member selected from the group consisting of a Baylonella parbula strain, a culture of the strain, a lysate of the strain, and an extract of the strain administered to a subject in need of treatment It provides a cancer prevention or treatment method comprising the step of doing.
  • the Bailonella parbula strain may be a KCTC 5019 strain.
  • the present invention is a use of a composition comprising at least one selected from the group consisting of a Baylonella parbula strain, a culture of the strain, a lysate of the strain, and an extract of the strain in the manufacture of a drug for preventing or treating cancer provides
  • the Bailonella parbula strain may be a KCTC 5019 strain.
  • the present invention provides a use for preventing or treating cancer of a pharmaceutical composition
  • a pharmaceutical composition comprising at least one member selected from the group consisting of a Bailonella parbula strain, a culture of the strain, a lysate of the strain, and an extract of the strain.
  • the Bailonella parbula strain may be a KCTC 5019 strain.
  • the pharmaceutical composition of the present invention may be used alone or in other therapies, such as surgery, radiation therapy, gene therapy, immunotherapy, bone marrow transplantation, stem cell transplantation, hormone therapy, targeted therapy, cryotherapy, ultrasound therapy, photodynamic therapy, chemotherapy. etc. can be performed.
  • therapies such as surgery, radiation therapy, gene therapy, immunotherapy, bone marrow transplantation, stem cell transplantation, hormone therapy, targeted therapy, cryotherapy, ultrasound therapy, photodynamic therapy, chemotherapy. etc. can be performed.
  • composition of the present invention may be administered in combination with an anti-cancer therapeutic agent. That is, the composition of the present invention may be a composition for concomitant administration of anticancer drugs.
  • composition of the present invention may further contain an anti-cancer agent.
  • the composition of the present invention may include the strain and the anticancer agent as a single agent, or may be included as separate agents.
  • the composition of the present invention may include a first agent containing a strain and a second agent including an anti-cancer agent.
  • the composition of the present invention may include the first agent and the second agent as separate and separate agents.
  • the first agent and the second agent may be administered through the same route of administration or different routes of administration.
  • the first agent and the second agent may be administered simultaneously or sequentially via the same route of administration or separate routes of administration.
  • the anticancer drug may be an anti-PD1 antibody.
  • the anticancer effect was confirmed when the Baylonella parbula KCTC 5019 (KBL1041) strain and the anti-PD1 antibody were treated in vitro , and the anti-PD1 antibody was the veil of the present invention. It can be included in the composition as an anti-cancer treatment that can be used in combination with Ronella parbula.
  • examples of anticancer therapeutics include chemotherapeutic agents, targeted anticancer therapeutics, and immunotherapeutic agents.
  • the immunotherapeutic agent is an immune checkpoint inhibitor, an immune checkpoint protein activity inhibitor, an immune checkpoint protein expression inhibitor, an immune cell therapy (eg, a tumor infiltrating lymphocyte, a T cell receptor or a chimeric antigen receptor cell therapy, etc.) and an anticancer agent. It may be at least one selected from vaccines.
  • an immunotherapeutic agent may be an immune checkpoint inhibitor.
  • the term “immune checkpoint inhibitor” refers to MHC class presentation, T cell presentation and/or differentiation, B cell presentation and/or differentiation, and cytokine, chemokine or immune cell proliferation and/or differentiation. It refers to any substance that prevents suppression of any mechanism in the immune system, such as signal transduction for cancer, and can treat cancer by suppressing immune evasion of cancer by blocking immune checkpoints that prevent the progression of immune responses in cancer with high immunosuppression. .
  • an anti-CTLA4 antibody as a non-limiting example of an immune checkpoint inhibitor
  • examples of anticancer therapeutics include chemotherapeutic agents, targeted anticancer therapeutics, and immunotherapeutic agents.
  • the immunotherapeutic agent is an immune checkpoint inhibitor, an immune checkpoint protein activity inhibitor, an immune checkpoint protein expression inhibitor, an immune cell therapy (eg, a tumor infiltrating lymphocyte, a T cell receptor or a chimeric antigen receptor cell therapy, etc.) and an anticancer agent. It may be at least one selected from vaccines.
  • an immunotherapeutic agent may be an immune checkpoint inhibitor.
  • the term “immune checkpoint inhibitor” refers to MHC class presentation, T cell presentation and/or differentiation, B cell presentation and/or differentiation, and cytokine, chemokine or immune cell proliferation and/or differentiation. It refers to any substance that prevents suppression of any mechanism in the immune system, such as signal transduction for cancer, and can treat cancer by suppressing immune evasion of cancer by blocking immune checkpoints that prevent the progression of immune responses in cancer with high immunosuppression. .
  • non-limiting examples of immune checkpoint inhibitors include anti-CTLA4 antibodies or antigen-binding fragments thereof; anti-PD-L1 antibody or antigen-binding fragment thereof; and one or more immune checkpoint inhibitors selected from the group consisting of anti-PD-1 antibodies or antigen-binding fragments thereof.
  • non-limiting examples of immune checkpoint inhibitors in the present invention include anti-PD-1 antibodies or antigen-binding fragments thereof.
  • Non-limiting examples of immune checkpoint inhibitors in the present invention include pembrolizumab, nivolumab, semiflamab, atezolizumab, avelumab, durvalumab, and/or ipilimumab and antigen-binding fragments thereof. there is.
  • composition of the present invention may exhibit a synergistic or additive effect on cancer alleviation, prevention, or treatment by being administered simultaneously with an immune checkpoint inhibitor or sequentially administered in combination with an immune checkpoint inhibitor.
  • synergistic or additive effects on tumor size reduction can be achieved by administering the composition of the present invention in combination with the aforementioned immune checkpoint inhibitor.
  • the cancer is lung cancer, non-small cell lung cancer, gastric cancer, liver cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin cancer (eg, melanoma), uterine cancer, ovarian cancer, colon cancer, colorectal cancer, breast cancer, uterine sarcoma , fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, esophageal cancer, laryngeal cancer, small intestine cancer, thyroid cancer, parathyroid cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, multiple myeloma, chronic or acute leukemia , may include at least one selected from the group consisting of childhood solid tumor, lymphoma, bladder cancer, renal cancer, renal cell carcinoma, renal pelvic carcinoma, axial contraction tumor, brain stem glioma, Merkel cell tumor, urinary tract tumor, and pituitary adenoma. .
  • cancer may include at least one selected from the group consisting of non-small cell lung cancer, melanoma, colorectal cancer, colorectal cancer, renal cancer, and liver cancer.
  • BMDC bone marrow-derived dendritic cells
  • splenocytes were isolated through magnetic-activated cell sorting (MACS).
  • MCS magnetic-activated cell sorting
  • the isolated bone marrow cells were cultured for 7 days and then in RPMI medium supplemented with 40 ng/ml GM-CSF, 10% PBS, 100 IU/ml penicillin/streptomycin and 50 ⁇ M 2-mercaptoethanol. It was cultured for 7 days in a 37 °C, 5% CO 2 humidity incubator, and divided and cultured every 3-4 days.
  • splenocytes and BDMC were treated with dead cells of various strains including the Bailonella parbula KBL1041 strain of the present invention at a ratio of 1:100 for 16 hours, and then the supernatant was obtained and ELISA was performed.
  • the Veillonella parbula KBL1041 strain of the present invention increased the secretion of the anti-cancer cytokines IFN- ⁇ and IL-12p70 compared to other strains, whereas the secretion of IL-10, one of the carcinogenic cytokines, decreased. It did not increase significantly compared to other strains (Fig. 1). Therefore, the group treated with the Baylonella parbula KBL1041 strain showed an excellent anti-cancer cytokine secretion effect by immune cells.
  • MC38 cells a colorectal cancer cell line isolated from mice with tumors, were co-cultured with the Bailonella parbula KBL1041 strain of the present invention or Akkermansia muciniphila , a control strain, and the control strain was tested by LDH-mediated cytotoxicity assay.
  • KBL1041 was analyzed to determine whether or not the ability to kill cancer cells was superior.
  • the isolated MC38 colorectal cancer cells were cultured in a 96-well culture plate one day prior to analysis of cell killing ability (5x10 3 cells/well).
  • MC38 cells were co-cultured with the KBL1041 strain of the present invention and the pasteurized Akkermansia muciniphila, a control strain, at a ratio of 1:10000, and when analyzed by co-culture with splenocytes, the ratio of MC38 cells to splenocytes was 1:1. 100 was co-cultured.
  • PBS was treated as a negative control group. Cytotoxicity was analyzed using CyQUANT LDH Cytotoxicity Assay (Invitrogen).
  • splenocytes co-cultured with KBL1041 showed better cancer cell killing ability (Cytotoxicity %) than splenocytes co-cultured with the control strain, but cancer cell killing ability was significant when only tumor cells were cultured without splenocytes. There was no difference (Fig. 2). This indicates that the Veillonella parbula KBL1041 strain of the present invention induces cell death by activating immune cells.
  • colon cancer cells MC38 and melanoma cells B16F10 were subcutaneously injected into 8-week-old C57BL/6 mice, and colon cancer cells CT26 cells were subcutaneously injected into BALB/c mice at 2.5x10 5 cells/100 ⁇ l, respectively. induced. From the 7th day after induction, 5x10 9 cells/200 ⁇ l/mouse of the prepared Bailonella parbula KBL1041 strain was intraperitoneally administered once every 3 days for a total of 3 times. In the case of oral administration, 1x10 12 cells/200 ⁇ l/mouse was administered daily from the 7th day after induction. PBS was administered as a negative control group.
  • the KBL1041 strain of the present invention had an effect of inhibiting tumor growth in mice induced with colorectal cancer or melanoma, and both intraperitoneal and oral administration were effective was able to confirm
  • immune cells were analyzed in the tumor tissues of the mice to which KBL1041 was administered through flow cytometry, and the ratios of NK cells, macrophages, monocytes, and neutrophils expressing specific components were confirmed.
  • the pasteurized KBL1041 strain of the present invention was intraperitoneally administered 4 times every 3 days to a mouse whose colon cancer was induced with MC38, a colon cancer cell, and then tissue, spleen and bone marrow tissue were collected from the mouse. Immune cells were analyzed by flow cytometry.
  • mice were injected with MC38, a colorectal cancer cell, to induce cancer, and from day 6 after induction, control IgG antibody and anti-Ly6G antibody, an anti-cancer drug, were intratumorally administered at 50 ⁇ g per mouse per day. did The next day after antibody administration, the Baylonella parbula KBL1041 strain of the present invention was intraperitoneally administered every 3 days. PBS was administered as a negative control group.
  • MC38 a colorectal cancer cell
  • NSGA mouse which is a mouse with normal functioning of only neutrophils, no T cells and natural killer cells, and functional disorders of dendritic cells and macrophages
  • the dead cells of the Baylonella parbula KBL1041 strain of the present invention were injected into the tumor. It was verified that the KBL1041 strain of the present invention exhibits anticancer efficacy by neutrophils, not other immune cells, by intraperitoneal administration at 5x10 9 cells/200 ⁇ l/mouse from day 7 after transplantation.
  • Bailonella parbula KBL1041 of the present invention increases the ratio of neutrophils and exhibits anticancer efficacy through neutrophils, regardless of the presence or function of other immune cells.
  • Example 7 Verification of relative expression level of genes related to neutrophil phenotype according to administration of Baylonella parbula KBL1041 strain
  • splenic neutrophils isolated from the mice were analyzed.
  • Relative expression levels of ccl2, icam1, il1b, tnfa, cxcl10 and cd206 genes associated with the neutrophil phenotype in isolated neutrophils were measured by real-time PCR.
  • Total RNA expressed from the splenic neutrophils was extracted, and then complementary cDNA was synthesized to confirm the expression level of the genes through RT-qPCR.
  • neutrophils were isolated from the spleen and co-cultured with MC38 cells at ratios of 1:10, 1:50, and 1:100 for 16 hours did.
  • neutrophils isolated from mice administered with KBL1041 showed a significantly increased cancer cell death rate (%) compared to neutrophils isolated from mice administered with PBS. was further increased (FIG. 9).
  • the Baylonella parbula KBL1041 of the present invention not only increased the simple anti-cancer phenotype of neutrophils but also increased the ability of neutrophils to kill cancer cells.
  • Example 9 Confirmation of the effect of increasing neutrophils having an anti-cancer phenotype when Baylonella parbula KBL1041 strain was administered to cancer-induced mice
  • Immune cells were analyzed in the tumor tissues of mice administered with KBL1041 through flow cytometry. After intraperitoneal administration of killed bacteria of the KBL1041 strain of the present invention to mice induced with colon cancer by MC38, flow cytometry analysis of tissue collected from the mice was compared with the results of analysis in the PBS-administered group treated as a negative control group, KBL1041 strain When treated, CD16+CD54+ neutrophils, which are neutrophils with an anticancer phenotype, increased (FIG. 10).
  • MFI mean fluorescence intensity
  • ROS reactive oxygen species
  • the Veillonella parbula KBL1041 strain of the present invention induces cancer cell death by increasing the secretion of ROS or NO from neutrophils.
  • Bailonella parbula KBL1041 strain of the present invention exhibits anticancer efficacy by specifically activating TLR2 of neutrophils.
  • C57BL/6 mice were injected with MC38, a colorectal cancer cell, to induce cancer, and from day 6 after induction, a control IgG antibody and an anti-TLR2 antibody, an anti-cancer drug, were intratumorally administered at 50 ⁇ g per mouse per day.
  • a control IgG antibody and an anti-TLR2 antibody, an anti-cancer drug were intratumorally administered at 50 ⁇ g per mouse per day.
  • the Baylonella parbula KBL1041 strain of the present invention was intraperitoneally administered every 3 days.
  • PBS was administered as a negative control group.
  • the KBL1041 strain of the present invention was administered as compared to the control PBS-administered mice. In one mouse, the effect of inhibiting tumor growth was significant. However, when anti-TLR2 antibody was administered to neutralize TLR2, the tumor growth inhibitory effect of the KBL1041 strain of the present invention disappeared (FIG. 14).
  • KBL1041 of the present invention activates TLR2 of neutrophils to induce anticancer function of neutrophils
  • the ability to kill cancer cells disappears when the KBL1041 strain of the present invention is treated with an anti-TLR2 antibody.
  • Spleen neutrophils were treated with 20 ⁇ g/ml anti-TLR2 antibody 4 hours before KBL1041 strain treatment, and MC38 cells were co-cultured with the neutrophils at a ratio of 1:100.
  • Neutrophils and killed KBL1041 strain were co-cultured at a ratio of 1:100.
  • cancer cell death rate (%) was significantly increased when treated with KBL1041 alone, but cancer cell death ability was rather decreased when treated in combination with an anti-TLR2 antibody (FIG. 15) .
  • C57BL/6 mice were injected with MC38, a colorectal cancer cell, to induce cancer, and from the 6th day after the induction, a control IgG antibody and an immuno-anticancer anti-PD1 antibody were intraperitoneally administered at 200 ⁇ g per mouse every 3 days. From the day following the start of antibody administration, on the 7th day after cancer induction, the Baylonella parbula KBL1041 strain of the present invention was intraperitoneally administered every 3 days. PBS was administered as a negative control group.
  • mice administered with PBS As a result of measuring the change in tumor volume and weight, in the case of mice administered with PBS, the tumor volume of mice administered with anti-PD1 antibody, an immuno-anticancer agent, was about 52.2%, compared to mice administered with control IgG antibody, and tumor volume was approximately 52.2%. Weight decreased by about 42.6% respectively.
  • tumor volume and tumor weight were reduced by about 65.1% and 63%, compared to mice administered with PBS, when control IgG antibody was administered without immunotherapy.
  • the tumor volume and tumor weight were reduced by 76.5% and 79.6% in mice administered with the KBL1041 strain of the present invention, compared to control mice administered with PBS.
  • the KBL1041 strain and the anti-PD1 antibody of the present invention were administered in combination, the tumor weight was reduced by about 68.4% and 79.6%, respectively, compared to the case of administering the KBL1041 strain or the anti-PD1 antibody alone (FIG. 16).
  • the Baylonella parbula KBL1041 strain of the present invention exhibits a combined effect with an immuno-anticancer agent, thereby confirming that the KBL1041 strain of the present invention can be used as an adjuvant to increase the reactivity of an immuno-anticancer agent did.
  • Example 14 Confirmation of the effect of reducing the viability of cancer cell lines of various carcinomas of the strain Baylonella parbula KBL1041
  • lung cancer cell line A549 breast cancer cell line MDA-MB-231, liver cancer cell line HepG2, melanoma cell line B16F10, pancreatic cancer cell line PANC1, renal cancer cell line RENCA and colorectal cancer cell line
  • the survival rate of cancer cells was measured.
  • each cancer cell was cultured in a 96-well culture plate, and the dead cells of the Bailonella parbula KBL1041 strain (pasteurization, 70 °C, 30 minutes) were 1:10 1 , 1:10 2 compared to the number of cancer cells. , 1:10 3 , 1:10 4 , 1:10 5 , and reacted for 24 to 72 hours. After 72 hours of strain treatment, cell viability was measured by dissolving formazan reduced by reductase in mitochondria in DMSO using an MTT assay kit (Promega, #G4000) and measuring absorbance at 570 nm.
  • MTT assay kit Promega, #G4000
  • the survival rate was significantly decreased in all types of cancer cell lines in a concentration-dependent manner after 72 hours of treatment with the KBL1041 strain (FIG. 17).
  • the KBL1041 strain of the present invention exhibits a growth inhibitory effect in various cancers such as lung cancer, breast cancer, liver cancer, melanoma, pancreatic cancer, kidney cancer, and colorectal cancer.
  • the lung cancer cell line A549 was cultured in a 6-well culture plate (A549: 1x10 4 cells/well, bottom agar: 0.6%, top agar: 0.3%), and the dead cells of the Baylonella parbula KBL1041 strain (pasteurization, 70 ° C.) , 30-minute method) was treated at a ratio of 1:10 2 , 1:10 3 to the number of cancer cells and cultured for 3 to 4 weeks. Then, in order to confirm the non-fixation formation reaction of the colorectal cancer cell line, it was observed through staining (0.005% Crystal violet in 10% NBF staining). After 3 to 4 weeks of treatment with the strain, the number of clusters, the size of the clusters, and the number of clusters of a certain size or larger were measured to analyze non-settled growth ability.
  • the KBL1041 strain of the present invention has an effect of inhibiting the ability of lung cancer cell lines to form non-settled cells.
  • RENCA a renal cancer cell line.
  • the renal cancer cell line RENCA was cultured in a 6-well culture plate (RENCA: 5x10 3 cells/well, bottom agar: 0.6%, top agar: 0.3%), and the dead cells of the Baylonella parbula KBL1041 strain (pasteurization, 70 °C, 30 minutes) was treated at a ratio of 1:10 2 , 1:10 3 to the number of cancer cells and cultured for 3 to 4 weeks. Then, in order to confirm the non-fixation formation reaction of the colorectal cancer cell line, it was observed through staining (0.005% Crystal violet in 10% NBF staining). After 3 to 4 weeks of treatment with the strain, the number of clusters, the size of the clusters, and the number of clusters of a certain size or larger were measured to analyze non-settled growth ability.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur l'utilisation d'une souche de Veillonella parvula pour la prévention, le traitement ou le soulagement du cancer.
PCT/KR2022/016090 2021-10-20 2022-10-20 Composition pour le soulagement, la prévention ou le traitement du cancer à l'aide d'une souche de veillonella parvula ayant une activité anticancéreuse Ceased WO2023068855A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0140316 2021-10-20
KR20210140316 2021-10-20

Publications (1)

Publication Number Publication Date
WO2023068855A1 true WO2023068855A1 (fr) 2023-04-27

Family

ID=86059550

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2022/016090 Ceased WO2023068855A1 (fr) 2021-10-20 2022-10-20 Composition pour le soulagement, la prévention ou le traitement du cancer à l'aide d'une souche de veillonella parvula ayant une activité anticancéreuse
PCT/KR2022/016092 Ceased WO2023068857A1 (fr) 2021-10-20 2022-10-20 Nouvelle souche bactérienne possédant une activité anticancéreuse et composition permettant de soulager, de prévenir ou de traiter le cancer l'utilisant

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/016092 Ceased WO2023068857A1 (fr) 2021-10-20 2022-10-20 Nouvelle souche bactérienne possédant une activité anticancéreuse et composition permettant de soulager, de prévenir ou de traiter le cancer l'utilisant

Country Status (2)

Country Link
KR (2) KR102881730B1 (fr)
WO (2) WO2023068855A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120944785A (zh) * 2025-10-17 2025-11-14 济南微生态生物医学省实验室 一株韦荣氏球菌zsjb6及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117625500B (zh) * 2024-01-24 2024-04-02 中山大学 一种胃梭菌及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190106732A (ko) * 2018-03-06 2019-09-18 주식회사 엠디헬스케어 베일로넬라 속 세균 유래 나노소포 및 이의 용도
KR20200118100A (ko) * 2018-02-06 2020-10-14 에벨로 바이오사이언시즈, 인크. 베일로넬라 박테리아를 이용한 암 및 면역 장애를 치료하기 위한 조성물 및 방법
WO2021142279A1 (fr) * 2020-01-10 2021-07-15 Evelo Biosciences, Inc. Compositions et procédés de traitement à l'aide de veillonella parvula

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
KR102644935B1 (ko) * 2016-12-22 2024-03-07 인스티튜트 구스타브 루시 항-PD1/PD-L1/PD-L2 항체에 대한 반응성의 마커로서의 미생물총 조성물, 및 항-PD1/PD-L1/PD-L2 Ab-기반 치료의 효능을 개선하기 위한 미생물 조정제의 용도
AR113011A1 (es) * 2017-09-08 2020-01-15 Evelo Biosciences Inc Vesículas extracelulares bacterianas
KR102323783B1 (ko) * 2017-09-22 2021-11-09 주식회사 고바이오랩 클로스트리디움 디피실레(Clostridium difficile) 성장 억제효과를 갖는 클로스트리디움 신덴스 균주
EP3476396A1 (fr) * 2017-10-31 2019-05-01 Institut Gustave Roussy Compositions bactériennes et cellulaires pour le traitement du cancer colorectal et procédés d'évaluation d'un pronostic pour des patients qui en souffrent
WO2019178542A1 (fr) * 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions pour moduler des populations de microflore intestinale, améliorer l'efficacité de médicaments et traiter le cancer, leurs procédés de fabrication et leurs méthodes d'utilisation
WO2020118232A1 (fr) * 2018-12-07 2020-06-11 President And Fellows Of Harvard College Identification de bactéries intestinales favorisant une réponse anti-tumorale à une immunothérapie
WO2020172492A2 (fr) * 2019-02-22 2020-08-27 Evelo Biosciences, Inc. Préparations de membrane bactérienne

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200118100A (ko) * 2018-02-06 2020-10-14 에벨로 바이오사이언시즈, 인크. 베일로넬라 박테리아를 이용한 암 및 면역 장애를 치료하기 위한 조성물 및 방법
KR20190106732A (ko) * 2018-03-06 2019-09-18 주식회사 엠디헬스케어 베일로넬라 속 세균 유래 나노소포 및 이의 용도
WO2021142279A1 (fr) * 2020-01-10 2021-07-15 Evelo Biosciences, Inc. Compositions et procédés de traitement à l'aide de veillonella parvula

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KEFAYAT AMIRHOSEIN, GHAHREMANI FATEMEH, ROSTAMI SOODABEH: "Veillonella parvula : a strictly anaerobic bacterium with high efficacy for safe and specific tumor targeting and colonization", BIORXIV, 11 May 2021 (2021-05-11), XP093059041, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.05.10.443531v1.full.pdf> DOI: 10.1101/2021.05.10.443531 *
KIM KIM SOON SOON SUN SUN, EUN JUNG WOO, CHO HYO JUNG, SONG DO SEON, KIM CHANG WOOK, KIM YOUNG SEOK, LEE SUNG WON, KIM YOON‐KEUN, : "Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 53, no. 4, 1 February 2021 (2021-02-01), GB , pages 540 - 551, XP093059045, ISSN: 0269-2813, DOI: 10.1111/apt.16200 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120944785A (zh) * 2025-10-17 2025-11-14 济南微生态生物医学省实验室 一株韦荣氏球菌zsjb6及其应用

Also Published As

Publication number Publication date
KR102881730B1 (ko) 2025-11-06
KR20230056619A (ko) 2023-04-27
KR20230057980A (ko) 2023-05-02
KR102859962B1 (ko) 2025-09-18
WO2023068857A1 (fr) 2023-04-27

Similar Documents

Publication Publication Date Title
WO2019216662A1 (fr) Souche de lactobacillus paracasei et utilisation associée
WO2019151843A1 (fr) Souche de lactobacillus plantarum kbl396 et son utilisation
WO2018164468A1 (fr) Souche de bacillus amyloliquefaciens gf423, et composition ayant des activités anti-oxydantes et anti-inflammatoires ou de prévention ou de traitement de l&#39;hyperlipidémie, y compris un polypeptide produit par celle-ci
WO2017131402A1 (fr) Nouvelle bactérie lactique dérivée d&#39;intestin humain ayant une fonction immunorégulatrice, et son utilisation
WO2022265430A1 (fr) Utilisation en polythérapie d&#39;une souche de lactobacillus fermentum et de cellules tueuses naturelles pour la prévention et le traitement de maladies métaboliques
WO2019226002A1 (fr) Souche de lactobacillus crispatus kbl693 et utilisation associée
WO2023068855A1 (fr) Composition pour le soulagement, la prévention ou le traitement du cancer à l&#39;aide d&#39;une souche de veillonella parvula ayant une activité anticancéreuse
WO2023055188A1 (fr) Nouveaux probiotiques et utilisation associée
WO2024048934A1 (fr) Nouvelle bactérie lactique lactiplantibacillus plantarum sko-001 pour réduire la graisse corporelle, et ses utilisations
WO2021261632A1 (fr) Nouvelle souche de faecalibacterium prausnitzii eb-fpdk11 et utilisation associée
WO2020262755A1 (fr) Nouvelle composition probiotique pour la régulation de l&#39;immunité intestinale
WO2014196775A1 (fr) Souche de lactobacillus brevis g-101 et son utilisation
WO2024136615A1 (fr) Lactobacillus présentant une activité prophylactique ou thérapeutique pour la colite et une activité antibactérienne contre les bactéries intestinales nuisibles et son utilisation
WO2024136036A1 (fr) Composition pour la prévention ou le traitement de l&#39;arthrite, contenant lactobacillus brevis ku15147
WO2021261929A1 (fr) Nouvelle souche de lactobacillus reuteri et utilisation associée
WO2022039561A1 (fr) Composition pour le traitement ou la prévention d&#39;une infection par clostridium difficile
WO2024162765A1 (fr) Nouvelles souches présentant une activité anti-helicobacter pylori et leurs utilisations
WO2024196187A1 (fr) Nouvelle souche latilactobacillus sakei cnsc001wb à fonction immunomodulatrice et son utilisation
WO2023058801A1 (fr) Composition pour soulager, prévenir ou traiter un trouble intestinal, comprenant une souche de lactobacillus acidophilus kbl402 ou kbl409
WO2024038980A1 (fr) Souche de lactobacillus plantarum ku15120 ou son utilisation
WO2020139020A2 (fr) Kimchi pour la prévention ou le traitement de maladies associées à helicobacter pylori
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l&#39;obésité ou de syndromes métaboliques induits par cette dernière
WO2023080552A1 (fr) Peptide ayant des activités physiologiques et son utilisation
WO2023277636A1 (fr) Composition anti-âge contenant une souche de lactobacillus sp. et une substance à base de plantes médicinales pour thérapie combinée
WO2019088590A2 (fr) Utilisation de mycobacterium paragordonae en immunothérapie anticancéreuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22884077

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22884077

Country of ref document: EP

Kind code of ref document: A1